https://www.selleckchem.com/products/ABT-888.html
Oral disease-modifying therapies, namely dimethyl fumarate, fingolimod and teriflunomide, have become standard treatments for multiple sclerosis. Clinical trials demonstrated a reduction in annual relapse rate, but real-world data is lacking, particularly in older adults. The objective of our study is to evaluate the real-world effectiveness of oral disease-modifying therapies among individuals with multiple sclerosis. We used Optum Clinformatics Data Mart, a large dataset representative of commercially insured individuals in the United
Like
Comment
Share
